BCPC officer has 430 shares withheld for taxes (BCPC)

Rhea-AI Filing Summary

BCPC senior vice president Frederic Boned reported a small tax‑related share withholding tied to equity compensation. On February 8, 2026, 430 shares of common stock were withheld at $173.16 per share to cover taxes on restricted shares granted on February 8, 2023. After this transaction, Boned directly owned 5,215 common shares and indirectly held 441 shares through a 401(k) plan.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Boned Frederic

Role SVP/GM, Human Nutri. & Health

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	430	$173.16	$74K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 5,215 shares (Direct); Common Stock — 441 shares (Indirect, 401(k) Plan)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Boned Frederic

(Last) (First) (Middle)

C/O BALCHEM CORPORATION

5 PARAGON DRIVE

(Street)

MONTVALE NJ 07645

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BALCHEM CORP [ BCPC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP/GM, Human Nutri. & Health

3. Date of Earliest Transaction (Month/Day/Year)
02/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/08/2026		F		430(1)	D	$173.16	5,215	D
Common Stock								441	I	401(k) Plan

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects shares that were withheld to cover withholding taxes due upon vesting of restricted shares (granted on 2/8/2023).

	/s/ Travis Larsen, Attorney in Fact for Frederic Boned	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BCPC executive Frederic Boned report on this Form 4?

Frederic Boned reported a tax-related share withholding, not an open-market trade. On February 8, 2026, 430 BCPC common shares were withheld at $173.16 each to cover taxes due on vesting restricted stock granted on February 8, 2023.

How many BCPC shares were withheld for taxes from Frederic Boneds award?

A total of 430 BCPC common shares were withheld for taxes. The withholding occurred on February 8, 2026 and related to the vesting of restricted shares originally granted on February 8, 2023, as noted in the footnote to the Form 4 filing.

How many BCPC shares does Frederic Boned own after the reported Form 4 transaction?

After the transaction, Frederic Boned directly owned 5,215 BCPC common shares. He also indirectly held 441 additional common shares through a 401(k) plan, according to the beneficial ownership details reported in the Form 4 filing for February 8, 2026.

Was Frederic Boneds BCPC Form 4 transaction an open-market sale?

No, the Form 4 shows a tax withholding, not an open-market sale. The code F indicates 430 shares were withheld by the issuer to satisfy withholding taxes when previously granted restricted shares vested on February 8, 2026.

What role does Frederic Boned hold at BCPC in this Form 4 filing?

In the filing, Frederic Boned is listed as an officer of the issuer. His specific title is SVP/GM, Human Nutri. & Health, indicating a senior leadership role overseeing the companys human nutrition and health business segment.